Johnson & Johnson has appointed María Pobre as General Manager of commercial operations for its Innovative Medicine business in Ireland, with a focus on accelerating patient access to innovative medicines.

Pobre brings more than 20 years of healthcare experience to the role, spanning launch excellence, market access and commercial operations across Europe and the US. According to Irish Medical Times, her experience includes pharmaceuticals and medical devices, with a career focus across oncology, specialty care, rare diseases and precision medicine access.

Pobre most recently served as Senior Franchise Director for Haematology, Pulmonary Hypertension and Neuroscience at Johnson & Johnson in Spain, where she led marketing and sales teams. She joined Johnson & Johnson in 2010 and has held roles covering commercial operations and market access.

The appointment places market access at the centre of Pobre’s remit in Ireland. She will lead the commercial business while working with health services, Government, patient groups, academia and industry partners to support timely access to treatments.

The strategic significance lies in the connection between pharmaceutical innovation and the healthcare systems required to deliver it. For medicines companies, developing new therapies is only one part of the process, with reimbursement, market access and engagement with healthcare stakeholders also influencing how quickly innovations reach patients.

Pobre’s background in oncology and rare diseases is particularly relevant to this challenge. These areas can involve complex treatment pathways and specialist healthcare requirements, making collaboration between pharmaceutical companies and healthcare stakeholders an important part of improving access to innovative therapies.

The appointment also comes as Ireland continues to position itself as a major European base for the life sciences industry. Johnson & Johnson Innovative Medicine Ireland operates across Ireland's pharmaceutical ecosystem, with activities spanning medicines and biopharmaceutical manufacturing alongside its commercial operations.

For pharmaceutical companies, leadership with experience across multiple markets can help connect global innovation strategies with local healthcare requirements. Pobre’s experience across Europe and the US provides a background for navigating the different commercial and market-access environments that influence the adoption of innovative medicines.

Her remit also extends beyond commercial activity. Pobre said she aims to work alongside healthcare services, Government, patient groups, academia and industry partners to ensure treatments deliver value for patients and the healthcare system, positioning stakeholder engagement as part of the access strategy.

The appointment therefore reflects a broader shift in pharmaceutical leadership towards linking innovation with outcomes and access. As therapies become more specialised, commercial leadership increasingly requires an understanding of healthcare systems, patient needs and the mechanisms that determine whether new treatments can reach those who need them. Johnson & Johnson has positioned Pobre’s appointment within this wider focus on advancing medicines and improving health outcomes in Ireland.

For the sector, the lesson is direct: pharmaceutical innovation only creates value when healthcare systems can access and deliver it. Leadership that combines commercial expertise with market-access experience can help bridge the gap between new medicines, healthcare stakeholders and the patients ultimately expected to benefit.

Source: Irish Medical Times / Johnson & Johnson Innovative Medicine Ireland / Johnson & Johnson